Apimeds Pharmaceuticals US (APUS) Total Liabilities (2023 - 2025)

Apimeds Pharmaceuticals US's Total Liabilities history runs 3 years deep, the most recent figure standing at $10.8 million for Q4 2025.

• Quarterly Total Liabilities rose 690.26% year-over-year to $10.8 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $10.8 million (up 690.26% YoY) and the FY2025 annual result came in at $10.8 million, up 690.26% from the prior year.
• Total Liabilities was $10.8 million for Q4 2025 at Apimeds Pharmaceuticals US, up from $1.1 million in the prior quarter.
• Across five years, Total Liabilities topped out at $10.8 million in Q4 2025 and bottomed at $390207.0 in Q4 2023.
• A 3-year average of $2.8 million and a median of $1.2 million in 2024 frame the typical range for Total Liabilities.
• Annual changes were most pronounced in 2024 — Total Liabilities surged 251.4% — and 2025, when it jumped 690.26%.
• Apimeds Pharmaceuticals US's Total Liabilities stood at $390207.0 in 2023, then jumped by 251.4% to $1.4 million in 2024, then soared by 690.26% to $10.8 million in 2025.
• Business Quant data shows APUS's Total Liabilities at $10.8 million in Q4 2025, $1.1 million in Q3 2025, and $809002.0 in Q2 2025.